Oxytocin levels are lower in premenopausal women with type 1 diabetes mellitus compared with matched controls
- 7 July 2014
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 31 (1) , 102-112
Abstract
Background: Oxytocin, a hormone most commonly associated with parturition and lactation, may have additional roles in diabetes complications. We determined oxytocin levels in premenopausal women with type 1 diabetes mellitus (T1DM) compared with non‐diabetic controls and examined associations of oxytocin with health behaviours, clinical factors, biomarkers, kidney function and bone health. Lower oxytocin was hypothesized for T1DM.Methods: A cross‐sectional study of premenopausal women with T1DM (n = 88) from the Wisconsin Diabetes Registry Study, a population‐based cohort of incident T1DM cases, and matched non‐diabetic controls (n = 74) was conducted.Results: Women with T1DM had lower oxytocin levels than controls adjusting for caffeine and alcohol use (p = 0.03). Health behaviours associated with oxytocin differed between women with and without T1DM: oxytocin was negatively associated with hormonal contraceptive use (quantified as lifetime contraceptive oestrogen exposure) in women with T1DM (p = 0.003), whereas positively related to hormonal contraceptive use (quantified as never/former/current) in controls (p < 0.001). Oxytocin had a positive association with adiposity (waist‐to‐hip ratio and leptin) in women with T1DM and a negative relationship with adiposity (weight gain) in controls. In T1DM only, oxytocin was positively associated with caffeine intake (p = 0.01) and negatively associated with alcohol use (p = 0.01). Oxytocin was not related to glycemic control, kidney function or bone health in T1DM.Conclusions: Oxytocin levels are lower in women with T1DM than matched controls. Oxytocin also has opposing associations with hormonal contraceptives and adiposity in women with and without T1DM. Research is needed to determine if the altered oxytocin milieu in T1DM is associated with oxytocinher health outcomes. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
Funding Information
- National Institutes of Health (R01DK036904)
- National Institutes of Health (K12HD055892)
- National Institutes of Health (UL1RR029879)
- American Diabetes Association (1-05-CR-35)
This publication has 39 references indexed in Scilit:
- Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapyTranslational Psychiatry, 2013
- Treatment of Obesity and Diabetes Using Oxytocin or Analogs in Patients and Mouse ModelsPLOS ONE, 2013
- Oxytocin and Psychological Factors Affecting Type 2 Diabetes MellitusExperimental Diabetes Research, 2012
- Mechanisms of the Anti-Obesity Effects of Oxytocin in Diet-Induced Obese RatsPLOS ONE, 2011
- Molecular, Immunohistochemical, and Pharmacological Evidence of Oxytocin’s Role as Inhibitor of Carbohydrate But Not Fat IntakeEndocrinology, 2010
- Downregulation of oxytocin and natriuretic peptides in diabetes: possible implications in cardiomyopathyThe Journal of Physiology, 2009
- Oxytocin is an anabolic bone hormoneProceedings of the National Academy of Sciences, 2009
- Gastroparesis is associated with oxytocin deficiency, oesophageal dysmotility with hyperCCKemia, and autonomic neuropathy with hypergastrinemiaBMC Gastroenterology, 2009
- Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetesOsteoporosis International, 2008
- Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKDAmerican Journal of Kidney Diseases, 2008